ML-7 Hydrochloride: Selective Myosin Light Chain Kinase Inhibitor

Executive Summary: ML-7 hydrochloride is a selective myosin light chain kinase (MLCK) inhibitor with a Ki of 300 nM, frequently used in cardiovascular and cell motility research (APExBIO product page). It has established efficacy in reducing myocardial injury in ischemia/reperfusion (I/R) models by modulating MLCK-mediated phosphorylation pathways (Dumont et al., 2000). ML-7 regulates phosphorylation of myosin light chains, affecting muscle contraction and cytoskeletal dynamics. The compound is soluble in DMSO and water but not ethanol, and is recommended to be stored at -20°C for stability (APExBIO). In vivo and in vitro findings demonstrate significant effects on cardiac contractility and endothelial barrier function, establishing ML-7 as a reproducible standard in preclinical research (vicrivirocmalate.com).

Biological Rationale

Myosin light chain kinase (MLCK) catalyzes the phosphorylation of myosin light chains (MLC), an essential process for actin-myosin cross-bridge cycling in muscle contraction. Dysregulation of MLCK activity has been directly linked to pathological conditions such as myocardial ischemia/reperfusion (I/R) injury, endothelial barrier dysfunction, and atherosclerosis. Targeted inhibition of MLCK by selective molecules like ML-7 hydrochloride enables precise modulation of cytoskeletal dynamics and cell motility in experimental models (APExBIO). ML-7's specificity for MLCK over other kinases provides an invaluable tool for dissecting the molecular underpinnings of cardiovascular and cytoskeletal diseases (vicrivirocmalate.com).

Mechanism of Action of ML-7 hydrochloride

ML-7 hydrochloride (1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride) functions as a competitive, ATP-binding site inhibitor of MLCK. By binding to the kinase domain, ML-7 blocks transfer of phosphate groups to myosin regulatory light chains, thus attenuating actin-myosin interaction and contractility. In cardiac myocytes, this translates to decreased MLC phosphorylation, modulating contractile force and energy metabolism. In endothelial cells, ML-7 suppresses MLCK-dependent tight junction protein phosphorylation, influencing vascular barrier integrity. The compound does not significantly inhibit non-MLCK kinases at standard working concentrations, ensuring high target selectivity (APExBIO).

Evidence & Benchmarks

• ML-7 hydrochloride exhibits a Ki of 300 nM for MLCK, demonstrating high potency (APExBIO).
• Pre-treatment with ML-7 in murine I/R models significantly preserves cardiac contractility by modulating MLC phosphorylation and upregulating citric acid cycle enzymes (Dumont et al., 2000).
• In neonatal rat cardiomyocytes, ML-7 inhibits restoration of sarcomeric organization induced by recombinant human neuregulin-1 (rhNRG-1) (vicrivirocmalate.com).
• ML-7 ameliorates endothelial dysfunction and atherosclerosis in animal models by regulating tight junction proteins ZO1 and occludin via MLCK inhibition (APExBIO).
• ML-7 is soluble in DMSO (≥15.95 mg/mL) and water (≥8.82 mg/mL with gentle warming/ultrasonic treatment), but insoluble in ethanol (APExBIO).

This article extends findings from 'ML-7 Hydrochloride in Ischemia/Reperfusion Models' by focusing on practical solubility and storage properties critical for reproducible cardiovascular workflows. For protocol-level optimization and scenario-driven applications, see 'ML-7 Hydrochloride (SKU A3626): Optimizing MLCK Inhibition', which this article complements by providing updated evidence on I/R injury and tight junction modulation. For cross-disease applications, 'ML-7 Hydrochloride: Precision MLCK Inhibition in Cardiovascular and Cancer Research' discusses ML-7's role in cancer models, whereas the present article restricts its scope to cardiovascular and endothelial research.

Applications, Limits & Misconceptions

ML-7 hydrochloride is widely applied in ischemia/reperfusion injury research, vascular endothelial dysfunction models, and studies of the cardiac myosin light chain kinase pathway. Its specificity enables dissection of MLCK-mediated phosphorylation of myosin light chain in both cardiac and vascular contexts. Researchers leverage ML-7 to modulate contractility, cytoskeletal organization, and tight junction integrity, making it a gold standard for preclinical cardiovascular studies (vicrivirocmalate.com).

Common Pitfalls or Misconceptions

• ML-7 hydrochloride should not be interpreted as a pan-kinase inhibitor; it is selective for MLCK and does not significantly inhibit other kinases at recommended concentrations (APExBIO).
• It is not suitable for studies requiring ethanol-based solvents due to insolubility in ethanol.
• ML-7 hydrochloride is for research use only; it is not approved for diagnostic or therapeutic use in humans.
• Long-term storage of ML-7 solutions above -20°C may result in degradation and loss of activity.
• Results in non-cardiovascular cell models (e.g., certain invertebrate lines) may not extrapolate due to pathway differences, as shown in cytoskeletal pathogen entry studies (blebbistatin.com).

Workflow Integration & Parameters

• Solubility preparation: Dissolve ML-7 hydrochloride in DMSO at ≥15.95 mg/mL or in water at ≥8.82 mg/mL with gentle warming and ultrasonic treatment; do not use ethanol.
• Storage: Store solid ML-7 hydrochloride at -20°C. Stock solutions are stable below -20°C for several months; avoid repeated freeze-thaw cycles.
• Recommended use: For in vivo I/R protocols, pre-treat animals with ML-7 before ischemia and during reperfusion for maximal contractile protection (Dumont et al., 2000).
• In vitro cell studies: Typical working concentrations range from 0.1–10 μM depending on model and endpoint; always validate for cytotoxicity and nonspecific effects (APExBIO).

Conclusion & Outlook

ML-7 hydrochloride, as provided by APExBIO, remains a benchmark tool for dissecting MLCK-dependent pathways in cardiovascular and endothelial research. Its proven efficacy in I/R injury models, reproducible solubility, and high selectivity make it essential for translational studies targeting cytoskeletal regulation. The robust evidence base supports its continued use in preclinical workflows investigating myocardial protection and endothelial function. Future advances are likely to optimize its application in combinatorial assays and multi-omic platforms, further refining our understanding of MLCK-mediated disease mechanisms (Dumont et al., 2000).